Metalloenzyme-like Activity of Alzheimer's Disease Β-Amyloid
Carlos Opazo,Xudong Huang,Robert A. Cherny,Robert D. Moir,Alex E. Roher,Anthony R. White,Roberto Cappai,Colin L. Masters,Rudolph E. Tanzi,Nibaldo C. Inestrosa,Bush
DOI: https://doi.org/10.1074/jbc.m206428200
2002-01-01
Abstract:β-Amyloid (Aβ) 1–42, implicated in the pathogenesis of Alzheimer's disease, forms an oligomeric complex that binds copper at a CuZn superoxide dismutase-like binding site. Aβ·Cu complexes generate neurotoxic H2O2 from O2 through Cu2+ reduction, but the reaction mechanism has been unclear. We now report that Aβ1–42, when binding up to 2 eq of Cu2+, generates the H2O2catalytically by recruiting biological reducing agents as substrates under conditions where the Cu2+ or reducing agents will not form H2O2 themselves. Cholesterol is an important substrate for this activity, as are vitamin C,l-DOPA, and dopamine (V maxfor dopamine=34.5 nm/min, K m = 8.9 μm). The activity was inhibited by anti-Aβ antibodies, Cu2+ chelators, and Zn2+. Toxicity of Aβ in neuronal culture was consistent with catalytic H2O2 production. Aβ was not toxic in cell cultures in the absence of Cu2+, and dopamine (5 μm) markedly exaggerated the neurotoxicity of 200 nm Aβ1–42·Cu. Therefore, microregional catalytic H2O2 production, combined with the exhaustion of reducing agents, may mediate the neurotoxicity of Aβ in Alzheimer's disease, and inhibitors of this novel activity may be of therapeutic value.